	US 12,247,046 B2
	Ribonucleic acids with 4′-thio-modified nucleotides and related methods
Frank DeRosa, Waltham, MA (US); and Michael Heartlein, Waltham, MA (US)
Assigned to Translate Bio, Inc., Cambridge, MA (US)
Filed by Translate Bio, Inc., Waltham, MA (US)
Filed on Aug. 10, 2022, as Appl. No. 17/818,858.
Application 17/818,858 is a continuation of application No. 17/032,485, filed on Sep. 25, 2020, granted, now 11,447,520.
Application 17/032,485 is a continuation of application No. 16/282,106, filed on Feb. 21, 2019, granted, now 10,822,368, issued on Nov. 3, 2020.
Application 16/282,106 is a continuation of application No. 14/776,506, granted, now 10,266,559, issued on Apr. 23, 2019, previously published as PCT/US2014/027422, filed on Mar. 14, 2014.
Claims priority of provisional application 61/785,098, filed on Mar. 14, 2013.
Prior Publication US 2023/0192753 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/67 (2006.01); C07H 21/02 (2006.01); A61K 9/1271 (2025.01); A61K 9/1272 (2025.01)

CPC C07H 21/02 (2013.01) [C12N 15/67 (2013.01); A61K 9/1271 (2013.01); A61K 9/1272 (2013.01); C12N 2310/3515 (2013.01)]

9 Claims

1. A lipid nanoparticle comprising:

at least one full-length mRNA molecule, wherein said full-length mRNA molecule has a coding region and, optionally, one or more non-coding regions,

encodes a full length protein, and

is at least 500 nucleotide residues in length, and

wherein 1%-20% of the total mRNA nucleotide residues of the full-length mRNA incorporate a 4′-thio-substituted furanose ring; and

wherein said lipid nanoparticle comprises a cationic lipid, a non-cationic lipid, a cholesterol-based lipid, and a PEGylated lipid; and

wherein said mRNA is encapsulated within said lipid nanoparticle.